Innocoll AG (NASDAQ:INNL) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday. The firm currently has a $3.75 target price on the specialty pharmaceutical company’s stock. Zacks Investment Research’s price target would suggest a potential upside of 23.76% from the company’s current price.
According to Zacks, “Innocoll Holdings develops and manufactures pharmaceutical products and medical devices through its proprietary collagen-based technologies. The company’s product include CollaGUARD(Ex-US), CollatampG(R), Septocoll(R), RegenePro(R), Collieva(R), CollaCare(R), Collexa(R) and Zorpreva(TM). It operates primarily in Asia, Australia, Canada, Europe, Latin America, the Middle East and the United States. Innocoll AG, formerly known as Innocoll GmbH, is headquartered in Athlone, Ireland. “
Several other brokerages have also recently weighed in on INNL. JMP Securities reiterated a “buy” rating on shares of Innocoll AG in a report on Sunday, November 6th. FBR & Co lowered their target price on Innocoll AG from $18.00 to $13.00 and set an “outperform” rating for the company in a report on Friday, November 4th.
Innocoll AG (NASDAQ:INNL) traded up 13.48% during midday trading on Wednesday, reaching $3.03. The company had a trading volume of 12,454 shares. Innocoll AG has a 1-year low of $2.20 and a 1-year high of $12.94. The company’s market capitalization is $73.79 million. The firm has a 50-day moving average of $4.60 and a 200 day moving average of $6.07.
Innocoll AG (NASDAQ:INNL) last announced its quarterly earnings data on Tuesday, November 22nd. The specialty pharmaceutical company reported ($0.51) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by $0.03. Innocoll AG had a negative net margin of 1,284.37% and a negative return on equity of 40,867.96%. On average, equities research analysts forecast that Innocoll AG will post ($2.34) EPS for the current year.
About Innocoll AG
Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically.